Where Valeant, and Corporate America, Went Wrong
Image: The big political story this week was the Republican presidential debate, and candidates’ usual complaints that too many Americans are falling behind economically. The big corporate governance story, meanwhile, has been the unraveling of Valeant Pharmaceuticals. The two are tied, Compliance Week editor Matt Kelly writes—since Valeant’s misplaced corporate ...
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
Valeant’s financial restatement begs compliance questions
Valeant Pharmaceuticals’ announced financial restatement raises questions about the drug company’s compliance program and its business model. But it might also serve as an early warning to all publicly listed U.S. companies about the increased room for misjudging the booking of sales once FASB rolls out its new revenue recognition ...
-
AnalysisCompliance pros need guaranteed job protections when speaking truth to power
Too often, compliance professionals do their jobs only to receive a pink slip at the end. Panelists at Compliance Week’s 20th Anniversary National Conference in Washington, D.C. this week said compliance professionals need regular access and reporting lines to CEOs and boards of directors, and to feel free to speak ...
-
News BriefBoards of directors have a lot of finance pros. It’s time for compliance to join too
More than half of the people who sit on corporate boards have a background in finance, with far fewer from compliance. But change may be coming. Panelists in a session of Compliance Week’s 20th National Conference in Washington, D.C., discussed the way boards of directors are changing in response to ...